NCT02827617 2025-11-18Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic LeukemiaOncology Institute of Southern SwitzerlandCompleted56 enrolled